Resistance to apoptosis should not be taken as a hallmark of cancer

查看全文 作　　者：Rui-An [1]Wang;Zeng-Shan [1]Li;Qing-Guo [1]Yan;Xiu-Wu [2]Bian;Yan-Qing [3]Ding;Xiang [4]Du;Bao-Cun [5]Sun;Yun-Tian [6]Sun;Xiang-Hong [7]Zhang

机构地区：[1]Department of Pathology, The Fourth Military Medical University;[2]Department of Pathology, The Third Military Medical University;[3]Department of Pathology, Nanfang Medical University;[4]Department of Pathology, Fudan University;[5]Department of Pathology, Tianjin Medical University;[6]Department of Pathology, Cancer Hospital of Chinese Academy for Medical Sciences;[7]Department of Pathology, Hebei Medical University

出　　处：《Chinese Journal of Cancer》索引2014年第33卷第2期,共4页

摘　　要：In the research community, resistance to apoptosis is often considered a hallmark of cancer. However, pathologists who diagnose cancer via microscope often see the opposite. Indeed, increased apoptosis and mitosis are usually observed simultaneously in cancerous lesions. Studies have shown that increased apoptosis is associated with cancer aggressiveness and poor clinical outcome. Furthermore, overexpression of Bcl-2, an antiapoptotic protein, is linked with better survival of cancer patients. Conversely, Bax, CD95, Caspase-3, and other apoptosis-inducing proteins have been found to promote carcinogenesis. This notion of the role of apoptosis in cancer is not new; cancer cells were found to be short-lived 88 years ago. Given these observations, resistance to apoptosis should not be considered a hallmark of cancer. 关键词：癌症患者抗凋亡蛋白 Caspase-3 抗细胞凋亡 BCL-2蛋白 BAX蛋白有丝分裂过度表达

相关文献

参考文献（31）
引证文献（16）
耦合文献（0）

参考文献(31)

引证文献(16)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Resistance to apoptosis should not be taken as a hallmark of cancer

参考文献(31)

引证文献(16)

用户提示